Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Total Liabilities (2016 - 2026)

Perspective Therapeutics' Total Liabilities history spans 16 years, with the latest figure at $63.3 million for Q1 2026.

  • On a quarterly basis, Total Liabilities rose 41.67% to $63.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $63.3 million, a 41.67% increase, with the full-year FY2025 number at $59.9 million, up 18.85% from a year prior.
  • Total Liabilities hit $63.3 million in Q1 2026 for Perspective Therapeutics, up from $59.9 million in the prior quarter.
  • Over the last five years, Total Liabilities for CATX hit a ceiling of $63.3 million in Q1 2026 and a floor of $2.9 million in Q1 2022.
  • Historically, Total Liabilities has averaged $31.9 million across 5 years, with a median of $44.7 million in 2025.
  • Biggest five-year swings in Total Liabilities: surged 558.51% in 2023 and later fell 16.07% in 2025.
  • Tracing CATX's Total Liabilities over 5 years: stood at $3.4 million in 2022, then surged by 558.51% to $22.7 million in 2023, then skyrocketed by 122.05% to $50.4 million in 2024, then grew by 18.85% to $59.9 million in 2025, then rose by 5.66% to $63.3 million in 2026.
  • Business Quant data shows Total Liabilities for CATX at $63.3 million in Q1 2026, $59.9 million in Q4 2025, and $52.6 million in Q3 2025.